Systematic Evaluation on the Efficacy of Ademetionine in Patients with Cholestatic Liver Diseases
Objective:To evaluate the efficacy of S-Adenosyl-L-Methionine(SAMe)in patients with cholestatic liver diseases. METHODS:Retrieved from Cochrane library,PubMed,CB M,VIP,CNKI,CMCC and Wanfang database,included randomized control ed trails(RCT)and qusi-randomized control ed trails(qRCT)were evaluated and analyzed using RevMan 5.0 software. RESULTS:5 studies were included,involving 428 patients.It showed that SAMe group (treatment group) provided better efficacy than control group in decreasing TBIL、DBil、ALT and AST in patients with cholestatic liver diseases,but similar efficacy to control group in increasing ALB.Subgroup analysis showed that in either 2 or 4 weeks treatment,treatment group was superior to control group for reducing TBIL and DBil;In 4 weeks treatment,treatment group was superior to control group for reducing ALT and AST, while ALT and AST decreased equal y in both groups in 2 weeks treatment.No obvious adverse drug reaction was reported.CONCLUSIONS:SAMe may abate jaundice and lower enzyme in patients with cholestatic liver diseases. It may enhance the therapeutic effect after proper protracted treatment.While more high-qualified studies are required to validate the therapeutic efficacy and safety.
NETL
NSTL
万方数据
